Dual-action GIP/GLP-1 in a daily capsule
Pricing varies by protocol
Tirzepatide's dual GIP/GLP-1 mechanism in an oral capsule, for patients who won't do injections. Absorption of this compounded oral formulation has not been studied, so we recommend the injectable first and will be straight with you about what that means. Taken on an empty stomach, with dosing guided by your provider based on your labs and response.
Licensed Providers · Lab-Guided · Ongoing Support
This treatment may be right for you if you identify with any of the following:
Explore alternative treatments your provider may recommend
Take the first step with a clinician-guided evaluation. Personalized protocols, compounded medications, ongoing support.
Take the Weight Loss QuizTirzepatide Oral Tablet at RenewRx starts at $499/month. That includes your provider consultation, protocol design, and lab monitoring every 90 days — there is no separate membership fee stacked on top. Final pricing depends on the dose and protocol your clinician prescribes after reviewing your bloodwork.
RenewRx dispenses compounded tirzepatide from a licensed 503A pharmacy. Compounded medications are prepared for an individual patient and are not FDA-approved. The FDA-approved branded version is Zepbound and Mounjaro (injectable). We'd rather tell you that plainly than let you assume otherwise — your provider will walk you through what it means before you start.
A daily oral capsule — no needles. Because it's swallowed rather than injected, absorption is less predictable than the injectable form, which is why your provider monitors your response closely.
We recommend the injectable, and we'll tell you why. The once-weekly injection is the form with clinical evidence behind it — the trial data, the dosing, the outcomes. Compounded oral tirzepatide has not been studied for absorption, so we can't give you a reliable timeline for this route. If needles are a genuine barrier for you, your provider will talk through the tradeoff honestly — but you should know you're choosing convenience over certainty.
Same gastrointestinal profile as injectable tirzepatide — nausea, constipation, diarrhea — typically worst after a dose increase. Some patients also report a bitter taste. Your provider reviews the full risk profile with you. Important: GLP-1 medications carry a boxed warning for thyroid C-cell tumors. They are not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Tell your provider if either applies to you.
Yes. Every RenewRx protocol begins with a lab panel reviewed by a licensed provider before anything is prescribed. We won't write a prescription off a questionnaire alone. Labs are rechecked every 90 days so your dose is adjusted to how you're actually responding — not to how you're expected to respond.
No — and we won't pretend otherwise. Tirzepatide injections have clinical trial data behind them. Compounded oral tirzepatide has never been studied for absorption, so its effectiveness is genuinely unknown. We offer it because needle aversion is real and a treatment you'll actually take beats one you avoid. But if you can tolerate the injection, take the injection.
Most of the benefit fades once you stop, because these therapies manage a condition rather than cure it. That said, the goal isn't to keep you on medication forever — your provider will talk with you about duration, tapering, and what an exit looks like. If a clinic never raises that conversation, ask why.
No contract, and no lock-in. Our protocols are structured as three-month programs because that's the window where the physiology actually shows up — hormone and peptide therapy needs time, plus at least one lab recheck, before anyone can honestly say whether it's working. You're committing to giving the protocol a fair trial, not to a contractual obligation.
Answers reviewed and approved by RenewRx clinical staff. This information is educational and is not medical advice or a substitute for evaluation by a licensed provider. Pricing reflects current protocols and may change.
